Sitemap
- Home
- Other topics
- Products
- ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
- About Hemophilia A
- Mechanism of half-life extension (MOE)
- Adult and adolescent study: Pharmacokinetics
- Adult and adolescent study: Trial Design
- Adult and adolescent study: Efficacy
- Adult and adolescent study: Safety
- Pediatric Study: Pharmacokinetics
- Pediatric Study: Trial Design
- Pediatric Study: Results
- Pediatric Study: Safety
- Dosing Regimen
- Dosing Calculator
- Resources for your patients
- HCP Resources
- Contact a Representative
- Beyfortus® (nirsevimab-alip) injection
- ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
- Therapeutic Areas
- Articles
- Sitemap